Madrigal Pharmaceuticals IncNASDAQ:MDGL
- LAST PRICE210.6700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots208.0000/ 1
- Ask / Lots234.0000/ 1
- Open / Previous Close--- / 210.6700
- Day Range---
- 52 Week Range
- Volume160
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MDGL |
|---|---|---|
| 09:32 ET | 892 | 203.18 |
| 09:34 ET | 808 | 205.7 |
| 09:39 ET | 500 | 203.5 |
| 09:45 ET | 500 | 204 |
| 09:48 ET | 8237 | 204.9999 |
| 09:50 ET | 8952 | 204.91 |
| 09:52 ET | 582 | 205.11 |
| 09:57 ET | 200 | 204.9 |
| 09:59 ET | 100 | 205.24 |
| 10:01 ET | 597 | 204.73 |
| 10:03 ET | 600 | 205.5 |
| 10:06 ET | 100 | 205 |
| 10:08 ET | 100 | 205.34 |
| 10:10 ET | 300 | 205.5 |
| 10:14 ET | 138 | 204.8855 |
| 10:17 ET | 900 | 205.5 |
| 10:19 ET | 8456 | 205.42 |
| 10:24 ET | 11240 | 205 |
| 10:26 ET | 35430 | 205.75 |
| 10:28 ET | 5318 | 206 |
| 10:30 ET | 1528 | 206.33 |
| 10:32 ET | 200 | 206.0401 |
| 10:33 ET | 501 | 206.4 |
| 10:35 ET | 200 | 206.75 |
| 10:37 ET | 500 | 206.94 |
| 10:39 ET | 400 | 206.71 |
| 10:42 ET | 3300 | 206.74 |
| 10:44 ET | 500 | 206.79 |
| 10:46 ET | 304 | 206.5 |
| 10:48 ET | 150 | 206.7385 |
| 10:50 ET | 200 | 206.635 |
| 10:51 ET | 100 | 206.85 |
| 10:53 ET | 136 | 206.4834 |
| 10:57 ET | 1300 | 206.98 |
| 11:00 ET | 1841 | 207 |
| 11:02 ET | 600 | 206.75 |
| 11:04 ET | 200 | 206.95 |
| 11:06 ET | 300 | 207 |
| 11:08 ET | 1808 | 207 |
| 11:09 ET | 1500 | 206.99 |
| 11:11 ET | 3718 | 207.94 |
| 11:13 ET | 300 | 208 |
| 11:15 ET | 400 | 207.99 |
| 11:22 ET | 400 | 207.99 |
| 11:26 ET | 800 | 208.45 |
| 11:29 ET | 200 | 208.47 |
| 11:31 ET | 200 | 208.235 |
| 11:33 ET | 700 | 208.1875 |
| 11:36 ET | 600 | 207.9 |
| 11:38 ET | 100 | 207.5 |
| 11:42 ET | 680 | 208.04887 |
| 11:47 ET | 700 | 207.765 |
| 11:49 ET | 2400 | 207.99 |
| 11:51 ET | 1000 | 208 |
| 11:54 ET | 100 | 207.77 |
| 11:56 ET | 1200 | 208 |
| 11:58 ET | 1000 | 208 |
| 12:00 ET | 8750 | 208.775 |
| 12:02 ET | 1502 | 209.8 |
| 12:03 ET | 500 | 210 |
| 12:05 ET | 1000 | 210 |
| 12:07 ET | 302 | 210 |
| 12:09 ET | 2400 | 209.98 |
| 12:12 ET | 7402 | 210.715 |
| 12:14 ET | 855 | 211.24 |
| 12:16 ET | 100 | 211.32 |
| 12:18 ET | 600 | 211.22 |
| 12:20 ET | 400 | 211.325 |
| 12:23 ET | 1000 | 211.5 |
| 12:30 ET | 400 | 212 |
| 12:32 ET | 600 | 212 |
| 12:34 ET | 1483 | 210.885 |
| 12:36 ET | 100 | 210.995 |
| 12:39 ET | 300 | 210.62 |
| 12:41 ET | 200 | 210.39 |
| 12:45 ET | 797 | 210.41 |
| 12:52 ET | 1575 | 209.7 |
| 12:54 ET | 200 | 209.68 |
| 12:59 ET | 110 | 209.775 |
| 01:01 ET | 2106 | 210.0794 |
| 01:06 ET | 410 | 210.024 |
| 01:14 ET | 100 | 209.885 |
| 01:19 ET | 890 | 209.5238 |
| 01:28 ET | 1350 | 209.94 |
| 01:30 ET | 200 | 209.8 |
| 01:32 ET | 664 | 209.558917 |
| 01:33 ET | 100 | 209.43 |
| 01:35 ET | 600 | 209.58 |
| 01:44 ET | 162838 | 211.72 |
| 01:46 ET | 700 | 211.355 |
| 01:48 ET | 932 | 210.515 |
| 01:50 ET | 400 | 211.2859 |
| 01:53 ET | 200 | 211.2146 |
| 01:55 ET | 4976 | 211.87 |
| 01:57 ET | 900 | 211.415 |
| 02:00 ET | 1551 | 211.716 |
| 02:02 ET | 100 | 211.97 |
| 02:04 ET | 100 | 211.91 |
| 02:06 ET | 100 | 211.65 |
| 02:08 ET | 100 | 211.92 |
| 02:09 ET | 300 | 211.82 |
| 02:11 ET | 200 | 211.58 |
| 02:13 ET | 300 | 211.71 |
| 02:15 ET | 1300 | 212 |
| 02:18 ET | 100 | 211.7242 |
| 02:20 ET | 2103 | 212 |
| 02:22 ET | 1400 | 212.01 |
| 02:27 ET | 764 | 212.49 |
| 02:29 ET | 100 | 212.5 |
| 02:31 ET | 910 | 212.445 |
| 02:33 ET | 100 | 212.61 |
| 02:36 ET | 100 | 212.79 |
| 02:38 ET | 1121 | 212.68 |
| 02:40 ET | 1490 | 212.975 |
| 02:42 ET | 1377 | 212.58 |
| 02:44 ET | 1598 | 212.11 |
| 02:45 ET | 400 | 211.93 |
| 02:47 ET | 400 | 211.775 |
| 02:49 ET | 100 | 211.515 |
| 02:51 ET | 400 | 211.21 |
| 02:54 ET | 300 | 210.998 |
| 02:56 ET | 400 | 210.74 |
| 02:58 ET | 200 | 210.4425 |
| 03:02 ET | 600 | 210.265 |
| 03:07 ET | 100 | 210.58 |
| 03:14 ET | 300 | 210.405 |
| 03:16 ET | 381 | 210.11 |
| 03:20 ET | 300 | 210.68 |
| 03:21 ET | 200 | 210.9 |
| 03:23 ET | 800 | 210.9408 |
| 03:27 ET | 600 | 211.42 |
| 03:30 ET | 1739 | 211.16 |
| 03:32 ET | 200 | 211.06 |
| 03:34 ET | 200 | 211.06 |
| 03:36 ET | 900 | 211.01 |
| 03:38 ET | 300 | 211.19 |
| 03:39 ET | 200 | 211.2 |
| 03:41 ET | 100 | 211.33 |
| 03:43 ET | 850 | 211.75 |
| 03:45 ET | 4433 | 211.844 |
| 03:48 ET | 1303 | 211.2101 |
| 03:50 ET | 1730 | 211.345 |
| 03:52 ET | 900 | 211.76 |
| 03:54 ET | 862 | 211.54 |
| 03:56 ET | 931 | 211.6476 |
| 03:57 ET | 2331 | 211.51 |
| 03:59 ET | 34289 | 210.67 |
Oct 23, 2024
DJ Madrigal Pharmaceuticals Is Maintained at Outperform by Oppenheimer, from 8:34AM ET on Wednesday Oct 23, 2024 by Dow Jones
8:34AM ET on Wednesday Oct 23, 2024 by Dow Jones
Oct 22, 2024
DJ Madrigal Pharmaceuticals Price Target Maintained With a $390.00/Share by HC Wainwright & Co., from 7:30AM ET on Tuesday Oct 22, 2024 by Dow Jones
7:30AM ET on Tuesday Oct 22, 2024 by Dow Jones
Oct 21, 2024
Oct 18, 2024
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024, from 8:00AM ET on Friday Oct 18, 2024 by Dow Jones
8:00AM ET on Friday Oct 18, 2024 by Dow Jones
Oct 2, 2024
Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference, from 8:00AM ET on Wednesday Oct 02, 2024 by Dow Jones
8:00AM ET on Wednesday Oct 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Madrigal Pharmaceuticals Inc | 4.6B | -8.3x | --- |
BridgeBio Pharma Inc | 4.5B | -9.0x | --- |
Immunovant Inc | 4.4B | -15.8x | --- |
Biohaven Ltd | 5.2B | -5.8x | --- |
Crinetics Pharmaceuticals Inc | 5.2B | -15.4x | --- |
Arcellx Inc | 4.5B | -80.2x | --- |
Company Information
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Contact Information
- Headquarters
- 200 Barr Harbor Dr Ste 400WEST CONSHOHOCKEN, PA, United States 19428-2978
- Phone
- 404-380-9263
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Julian Baker
- President, Chief Executive Officer, Director
- Bill Sibold
- Chief Financial Officer, Senior Vice President
- Mardi Dier
- President of Research and Development, Chief Medical Officer, Director
- Rebecca Taub
- Senior Vice President - Clinical Development
- Michael Charlton
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.6B |
|---|---|
Revenue (TTM) | $14.6M |
Shares Outstanding | 21.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.45 |
EPS | $-25.50 |
Book Value | $20.39 |
P/E Ratio | -8.3x |
Price/Sales (TTM) | 312.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,622.65% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
